• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Investing ‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher
Investing

‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher

by January 9, 2023
by January 9, 2023 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

Shares of Biogen Inc (NASDAQ: BIIB) have gained nearly 45% since late September but CEO Christopher Viehbacher says there’s still “a lot that’s underestimated” at Biogen.  

Highlights from CEO’s interview with CNBC

Viehbacher is convinced that the likes of “Lecanemab” and “Zuranolone” will contribute significantly to future growth. Speaking this morning with CNBC’s Meg Tirrell, he noted:

“We’ve got two great products to launch. We have Zuranolone, a novel new antidepressant. One of the first new antidepressants in a couple of decades. So, that’s already exciting. I think both of those products will be quite significant.”

At the end of its latest reported quarter, Biogen had over $5.70 billion in cash, equivalents, and marketable securities that the Chief Executive said was sufficient to drive external growth.

Moving forward, he expects the cost side of things to help with growth as well.

Its Alzheimer drug received accelerated approval

Last week, the Food and Drug Administration (FDA) granted accelerated approval for Lecanemab – the Alzheimer drug that Biogen developed in collaboration with the Japanese Eisai Co.

According to CEO Viehbacher, CMS could start providing coverage for this treatment in the back half of 2023.

I think, to a degree, Alzheimer’s is an underestimated disease when I hear, well, maybe it’s a little memory loss. It’s a devastating fatal disease. And this is the first time we’ve actually seen a product that’s demonstrated benefit.

In a clinical trial, Lecanemab was shown to be effective in slowing cognitive decline by 27% over 18 months as Invezz reported here. Wall Street currently has a consensus “overweight” rating on the biotech stock.

The post ‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher appeared first on Invezz.

You Might Also Like
  • Diagonal Spread Options Strategy: The Ultimate Guide
  • What made Logitech shares lose 20% on Thursday?
  • Analyst reveals a ‘rare retailer with momentum’ to own in 2023
  • MULN stock price forecast: Is it safe to buy Mullen Automotive?
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Lululemon stock sinks following lowered outlook: buy the dip?
next post
25+ US economy statistics: forecast, trends and facts for 2023

You may also like

Fairlead’s Katie Stockton expects new market lows in 2023

January 3, 2023

Cramer recommends caution as stocks rally on inflation data

December 13, 2022

Jim Cramer likes Tesla shares at current price

December 5, 2022

Netflix stock is the ‘best recession play’ for 2023: Analyst

December 12, 2022

Opera launches new Web3 security tools for crypto users

December 15, 2022

JD Sports shares collapsed in 2022: Is it a buy...

December 21, 2022

What Are Covered Calls And How Do They Work?

May 18, 2024

CAC 40 forecast for December 2022

November 30, 2022

Long Call Vs. Short Put

August 29, 2023

XPeng stock rises 48% from a double-bottom pattern. Should you...

December 1, 2022

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

      May 31, 2025
    • Leadership Rotation Could Confirm Corrective Phase

      May 30, 2025
    • Run Your Stock Portfolio Like a Pro Sports Team

      May 30, 2025
    • U.S. foreign tax bill sends jitters across Wall Street

      May 30, 2025
    • Amazon taps Xbox co-founder to lead new team developing ‘breakthrough’ consumer products

      May 30, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,765 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,472 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,451 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,432 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,308 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,106)
    • Investing (538)
    • Stock (2,581)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right...

      May 31, 2025
    • Leadership Rotation Could Confirm Corrective Phase

      May 30, 2025
    • Run Your Stock Portfolio Like a Pro Sports Team

      May 30, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,106)
    • Investing (538)
    • Stock (2,581)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    2 bullish takes from yesterday’s FOMC...

    November 24, 2022

    Core inflation remains high, meaning more...

    December 19, 2022

    Amazon Web Services will take a...

    December 5, 2022
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here